The results of therapy with venetoclax, daratumumab and plerixafor as part of the conditioning regimen in chemotherapy-refractory acute leukemia in children
Authors:
- Maria KlimentovaMKMaria Klimentova
- Лариса ШелиховаЛШЛариса Шелихова
- M. A. IlushinaMIM. A. Ilushina
- S. BlagovSBS. Blagov
- M. E. PerminovaMPM. E. Perminova
- А. М. ПоповАПА. М. Попов
- S. A. KashporSKS. A. Kashpor
- Maria FadeevaMFMaria Fadeeva
- Yulia OlshanskayaYOYulia Olshanskaya
- Svetlana GlushkovaSGSvetlana Glushkova
- Dmitry PershinDPDmitry Pershin
- Dmitry BalashovDBDmitry Balashov
Open Access
- 31 July 2023
- journal article
- research article
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 22 (2) , 14-27-27
Abstract
The main outcomes of allogeneic hematopoietic stem cell transplantation (HSCT) in chemotherapy-refractory acute leukemia remain suboptimal due to a high relapse rate. The incorporation of targeted anti-leukemia agents into the conditioning regimens is a potential approach to improve the efficacy of HSCT. We assessed the safety and potential efficacy of the addition of venetoclax, daratumumab, and plerixafor to the conditioning regimens in children with chemotherapy-refractory acute leukemias who received allogeneic TCRab/CD19-depleted HSCT. We used data from a pilot study, as well as the data of patients from a retrospective cohort who received similar therapy according to the individual indications. The study was approved by the Independent Ethics Committee and the Scientific Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. All 43 patients (33 acute myeloid leukemias (AML), 8 T-cell acute lymphoblastic leukemias (T-ALL) and 2 acute leukemias of ambiguous lineage) had active disease status at the time of transplantation. The preparative regimen included myeloablative conditioning based on either total body irradiation or treosulfan or melphalan. A haploidentical related donor was used as a graft source in 38 cases, while a fully matched related or unrelated donor was used in 5 cases. The engraftment was observed in 93% of cases, no excessive toxicity was noted. MRD-negative complete remission was achieved in 37 patients (86%). The cumulative incidence of grade II–IV acute graft-versus-host disease (GvHD) was 10%, and the cumulative incidence of chronic GvHD was 5%. At 2 years, transplant-related mortality was 7%, relapse incidence was 52%, event-free survival was 41%, and overall survival was 51%. The overall survival rate for the AML group was 58% and 25% for the T-ALL group. Our data show that the addition of targeted agents to the conditioning regimens is safe, however, does not significantly improve the results of HSCT in the study cohort of patients.Keywords
This publication has 46 references indexed in Scilit:
- Improved immune recovery after transplantation of TCRαβ/CD19-depleted allografts from haploidentical donors in pediatric patientsBone Marrow Transplantation, 2015
- Leukemia cell mobilization with G-CSF plus plerixafor during busulfan–fludarabine conditioning for allogeneic stem cell transplantationBone Marrow Transplantation, 2015
- NIH Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. The 2014 Pathology Working Group ReportTransplantation and Cellular Therapy, 2015
- CXCR4 expression accounts for clinical phenotype and outcome in acute myeloid leukemiaCytometry Part B: Clinical Cytometry, 2014
- The Prognostic Value of CXCR4 in Acute Myeloid LeukemiaApplied Immunohistochemistry & Molecular Morphology, 2013
- Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantationLeukemia, 2012
- Hematopoietic Stem-Cell Transplantation for Acute Leukemia in Relapse or Primary Induction FailureJournal of Clinical Oncology, 2010
- Sustained Remissions of High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome After Reduced-Intensity Conditioning Allogeneic Hematopoietic Transplantation: Chronic Graft-Versus-Host Disease Is the Strongest Factor Improving SurvivalJournal of Clinical Oncology, 2008
- A large-scale method for the selective depletion of αβ T lymphocytes from PBSC for allogeneic transplantationCytotherapy, 2007
- Assessment of Bcl-2 Expression as Modulator of Fas Mediated Apoptosis in Acute LeukemiaHematology, 2004